LO-CD 2a強烈抑制混合淋巴細胞培養（MLC）3并誘導T細胞凋亡。此外，LO-CD 2a不誘導靜息T細胞的增殖，并且抑制由OKT 3抗體誘導的T細胞增殖，誘導非常低水平的細胞因子釋放，并且還抑制由OKT 3誘導的細胞因子產生。LO-CD 2a強烈抑制用可溶性OKT 3刺激的外周血單核細胞的增殖，并且誘導人T細胞低反應性。將LO-CD 2a添加至原代MLC抑制T細胞增殖應答，并對繼發性免疫應答具有后續抑制作用，從而阻斷原代和記憶性同種異體抗原增殖應答。二次MLC中的人T細胞低反應性僅限于同種異體抗原，并且在不存在抗體的情況下和在細胞表面重新表達CD 2之后都發生 抗人CD 2（LO-CD 2a）體內抗體原液該產品同種型對照：Rat IgG2b In Vivo Isotype Control - Low Endotoxin [1-2] (ICH2243) 緩沖液：ICH3001-100ml，nICH3002-100ml，nICH3003-100ml， 濃度：≥ 2.0 mg/ml 純度：>95% by SDS-PAGE 內毒素：<1.0 EU/mg as determined by the LAL method 制劑：Sterile, preservative-free, solution in PBS. BSA and Azide free.
應用類型
ELISA, Functional Assays, Flow Cytometry
免疫原
LO-CD2a was developed as an immunosuppressive agent for use in organ allotransplantation. LO-CD2a was produced by immunizing a LOU/C rat with purified human T lymphocytes and fusing the splenocytes with the non-secreting rat fusion cell line IR983F, resulting in a rat IgG2b mAb of the IgK-1a allotype
